Answers are grounded in this paper and cite their sources.
Longitudinal profiling identifies IFN-gamma as a key predictor of immunotherapy response in advanced gastric cancer, suggesting further biomarker validation is needed.
IFN-gamma emerges as a critical biomarker for prognostic assessment and therapeutic monitoring in advanced GC immunotherapy, and its composite model incorporating PD-L1 Combined Positive Score (CPS) demonstrated superior predictive efficacy, highlighting the necessity for validating additional biomarkers in future clinical studies.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: